Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia.

Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC.

Blood. 2013 Jan 17;121(3):476-84. doi: 10.1182/blood-2012-08-450585. Epub 2012 Dec 3.

2.

Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia.

Morris JC, Janik JE, White JD, Fleisher TA, Brown M, Tsudo M, Goldman CK, Bryant B, Petrus M, Top L, Lee CC, Gao W, Waldmann TA.

Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):401-6. Epub 2005 Dec 30.

3.

NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.

Yu J, Mitsui T, Wei M, Mao H, Butchar JP, Shah MV, Zhang J, Mishra A, Alvarez-Breckenridge C, Liu X, Liu S, Yokohama A, Trotta R, Marcucci G Jr, Benson DM, Loughran TP Jr, Tridandapani S, Caligiuri MA.

J Clin Invest. 2011 Apr;121(4):1456-70. doi: 10.1172/JCI43242.

4.

Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia.

Chen J, Petrus M, Bamford R, Shih JH, Morris JC, Janik JE, Waldmann TA.

Blood. 2012 Jan 5;119(1):137-43. doi: 10.1182/blood-2011-04-346759. Epub 2011 Nov 2.

5.

Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.

Votavova P, Tomala J, Kovar M.

Immunol Lett. 2014 May-Jun;159(1-2):1-10. doi: 10.1016/j.imlet.2014.01.017. Epub 2014 Feb 7. Review.

PMID:
24512738
6.

Targeting IL-15 in large granular lymphocyte leukemia.

Steinway SN, Loughran TP.

Expert Rev Clin Immunol. 2013 May;9(5):405-8. doi: 10.1586/eci.13.28.

7.

Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.

Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, Murakawa T, Nakajima J, Matsushita H, Kakimi K.

Cytotherapy. 2013 Apr;15(4):481-91. doi: 10.1016/j.jcyt.2012.12.004. Epub 2013 Feb 5.

PMID:
23391461
8.
9.

IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells.

Yu P, Bamford RN, Waldmann TA.

Eur J Immunol. 2014 Nov;44(11):3330-41. doi: 10.1002/eji.201444675.

10.

The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders.

Waldmann TA.

J Investig Dermatol Symp Proc. 2013 Dec;16(1):S28-30. doi: 10.1038/jidsymp.2013.8. Review.

11.

Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes.

Yokoyama S, Watanabe N, Sato N, Perera PY, Filkoski L, Tanaka T, Miyasaka M, Waldmann TA, Hiroi T, Perera LP.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15849-54. doi: 10.1073/pnas.0908834106. Epub 2009 Sep 1.

12.

Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of γδ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With αβ T-Cell Large Granular Lymphocytic Leukemia. [corrected].

Yabe M, Medeiros LJ, Wang SA, Konoplev S, Ok CY, Loghavi S, Lu G, Flores L, Khoury JD, Cason RC, Young KH, Miranda RN.

Am J Clin Pathol. 2015 Oct;144(4):607-19. doi: 10.1309/AJCPJSA1E1YWSZEY. Erratum in: Am J Clin Pathol. 2015 Nov;144(5):823.

PMID:
26386082
13.

Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo.

Finch DK, Midha A, Buchanan CL, Cochrane D, Craggs RI, Cruwys S, Grahames C, Kolbeck R, Lowe DC, Maltby J, Pattison DV, Vousden KA, Ward A, Sleeman MA, Mallinder PR.

Br J Pharmacol. 2011 Jan;162(2):480-90. doi: 10.1111/j.1476-5381.2010.01061.x.

14.

Different dynamics of IL-15R activation following IL-15 cis- or trans-presentation.

Perdreau H, Mortier E, Bouchaud G, Solé V, Boublik Y, Plet A, Jacques Y.

Eur Cytokine Netw. 2010 Dec;21(4):297-307. doi: 10.1684/ecn.2010.0207. Epub 2010 Nov 16.

15.

Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes.

Hunter MR, Prosser ME, Mahadev V, Wang X, Aguilar B, Brown CE, Forman SJ, Jensen MC.

Mol Immunol. 2013 Nov;56(1-2):1-11. doi: 10.1016/j.molimm.2013.03.021. Epub 2013 Apr 27.

PMID:
23628622
16.

Anti-gamma chain and anti-IL-2Rbeta mAbs in combination with donor splenocyte transfusion induce H-Y skin graft acceptance in murine model.

Chang S, Chen BC, Du DF, Zhou J, Zhang X, Chen ZH.

Transplant Proc. 2009 Nov;41(9):3913-5. doi: 10.1016/j.transproceed.2009.06.223.

PMID:
19917411
17.

In vivo maintenance of human regulatory T cells during CD25 blockade.

Huss DJ, Mehta DS, Sharma A, You X, Riester KA, Sheridan JP, Amaravadi LS, Elkins JS, Fontenot JD.

J Immunol. 2015 Jan 1;194(1):84-92.

18.

Humanized antibody directed to the IL-2 receptor beta-chain prolongs primate cardiac allograft survival.

Tinubu SA, Hakimi J, Kondas JA, Bailon P, Familletti PC, Spence C, Crittenden MD, Parenteau GL, Dirbas FM, Tsudo M, et al.

J Immunol. 1994 Nov 1;153(9):4330-8.

PMID:
7930631
19.

IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.

Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK, Tso JY, Waldmann TA.

Cancer Res. 2000 Dec 15;60(24):6977-84.

20.

Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias.

Hodge DL, Yang J, Buschman MD, Schaughency PM, Dang H, Bere W, Yang Y, Savan R, Subleski JJ, Yin XM, Loughran TP Jr, Young HA.

Cancer Res. 2009 May 1;69(9):3986-94. doi: 10.1158/0008-5472.CAN-08-3735. Epub 2009 Apr 14.

Supplemental Content

Support Center